8-K: Lifeloc Technologies Secures $750,000 in Subordinated Debt Financing to Fuel Growth and SpinDx Development

Lifeloc Technologies has secured $750,000 in subordinated debt financing from Diamond Bridge Capital, along with a warrant to purchase shares, to support growth and the commercialization of its SpinDx technology.

Summary

• Lifeloc Technologies has entered into a subordinated debenture purchase agreement with Diamond Bridge Capital, securing $750,000 in funding.
• The debenture carries an 8.25% annual interest rate and matures on December 31, 2030.
• The agreement includes a warrant for Diamond Bridge Capital to purchase up to 62,500 shares of Lifeloc's common stock at $4.50 per share.
• Lifeloc will make quarterly interest-only payments until December 2025, followed by monthly principal and interest payments starting January 2026, based on a 10-year amortization schedule.
• The funds will be used for general corporate purposes, including the development and commercialization of the SpinDx technology.
• The company has provided forward-looking financial projections, anticipating revenue growth from $8.5 million in 2024 to $19.5 million in 2028, driven by SpinDx.
• Lifeloc expects SpinDx to provide rapid, on-site drug testing results at a cost of around $25 per test, compared to current lab costs of $100-$300.
• The company plans to have high volume automation equipment and experienced personnel to produce the SpinDx disks in-house by the time the system is market-ready, planned for Q4 2025.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a new financing agreement and the potential of the SpinDx technology. However, there are risks associated with the development and commercialization of the technology, and the company is projecting losses for the next few years.

Positives

• The $750,000 financing provides capital for growth and the development of the SpinDx technology.
• The warrant agreement could provide additional capital to the company if exercised.
• The SpinDx technology has the potential to disrupt the drug testing market with its rapid and cost-effective on-site testing capabilities.
• The company has a clear plan to bring the SpinDx technology to market, including beta testing and in-house production.
• Lifeloc's existing presence in the alcohol breathalyzer market could provide a competitive advantage for the SpinDx product.

Negatives

• The debenture is subordinated to the company's obligations to its general and secured creditors, increasing the risk for the lender.
• The company is projecting losses before tax for 2024, 2025 and 2026.
• The company is reliant on a third party for initial production of the SpinDx disks.
• The company is reliant on the successful commercialization of SpinDx to achieve its projected revenue growth.

Risks

• The company may not successfully commercialize the SpinDx technology within the projected timeframe or at all.
• The company may not achieve the expected market adoption of its technology solutions.
• The company may be unable to produce its solutions at the anticipated cost or offer them at the expected prices.
• The company may fail to raise sufficient additional capital to complete its research and development plans.
• The company is subject to risks outlined in its filings with the Securities and Exchange Commission.

Future Outlook

Lifeloc anticipates significant revenue growth driven by the commercialization of its SpinDx technology, with plans to integrate it with their existing breathalyzer products and expand into the marijuana breathalyzer market. The company projects revenue to reach $19.5 million by 2028.

Management Comments

• Wayne Willkomm, CEO of Lifeloc Technologies, stated that the financing marks an important step forward for Lifeloc as they expand their capabilities and build on their legacy of innovation.
• Vern Kornelsen, Lifeloc's Chief Financial Officer, believes SpinDx will drive the same evolution in drug testing as the personal computer did in data processing.
• Willkomm added that the strategic funding reinforces their financial stability and enables them to stay at the forefront of technological advancements.

Industry Context

The financing and development of SpinDx align with the growing demand for rapid, on-site drug testing solutions. The current industry practice of sending samples to outside labs is time-consuming and expensive, creating an opportunity for technologies like SpinDx to disrupt the market. The company is positioning itself to compete with other companies developing similar technologies.

Comparison to Industry Standards

• The document highlights the current industry standard of sending drug testing samples to outside labs, which can take a day or more and cost $100-$300 per test.
• Lifeloc's SpinDx technology aims to provide results within minutes at a cost of around $25 per test, which is a significant improvement over current standards.
• While the document mentions that there are other efforts underway to capture this market, it positions SpinDx as unique in its ability to accurately and quickly process the sample and provide a quantitative result.
• The document does not provide specific comparisons to other companies or projects, but it implies that SpinDx is a superior solution to existing technologies.

Stakeholder Impact

• Shareholders may benefit from the potential growth and innovation driven by the financing and SpinDx technology.
• Employees may have opportunities for growth and development as the company expands.
• Customers may benefit from the availability of rapid and cost-effective drug testing solutions.
• Suppliers may see increased demand for their products and services as the company scales up production.
• Creditors may be impacted by the subordinated nature of the debt.

Next Steps

• Lifeloc will continue to develop and refine the SpinDx technology.
• The company will conduct beta testing of the SpinDx readers at several sites.
• Lifeloc plans to reduce the size of the SpinDx prototype reader by 25%.
• The company will acquire high volume automation equipment and hire experienced personnel to produce the SpinDx disks in-house.
• Lifeloc will file a registration statement with the SEC for the resale of the shares underlying the warrant issued to Diamond Bridge Capital.

Key Dates

Keywords

subordinated debt, financing, warrant, SpinDx, drug testing, breathalyzer, technology, microfluidics, research and development, capital raise